MCID: CLN015
MIFTS: 50

Colon Adenocarcinoma malady

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colon Adenocarcinoma

Aliases & Descriptions for Colon Adenocarcinoma:

Name: Colon Adenocarcinoma 12 13 52 14
Adenocarcinoma of Colon 12 69
Adenocarcinoma of the Colon 12
Colonic Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:234
NCIt 47 C4349
SNOMED-CT 64 255082000
UMLS 69 C0338106

Summaries for Colon Adenocarcinoma

Disease Ontology : 12 A colon carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colon Adenocarcinoma, also known as adenocarcinoma of colon, is related to keratosis palmoplantaris adenocarcinoma of the colon and submucosal invasive colon adenocarcinoma. An important gene associated with Colon Adenocarcinoma is BAX (BCL2 Associated X, Apoptosis Regulator), and among its related pathways/superpathways are Development HGF signaling pathway and Pathways in cancer. The drugs Oxaliplatin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and lung, and related phenotypes are cellular and digestive/alimentary

Related Diseases for Colon Adenocarcinoma

Diseases related to Colon Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 168)
id Related Disease Score Top Affiliating Genes
1 keratosis palmoplantaris adenocarcinoma of the colon 12.0
2 submucosal invasive colon adenocarcinoma 11.9
3 colon mucinous adenocarcinoma 10.9
4 adenocarcinoma 10.9
5 adult myxoid chondrosarcoma 10.3 CTNNB1 KRT20
6 acute myocardial infarction 10.3 ABCB1 NQO1 TYMS
7 granulocytopenia 10.3 CDH1 CTNNB1 KRT20
8 cyanide-induced parkinsonism 10.3 CALB2 CDH1
9 bladder carcinoma in situ 10.3 CEACAM5 FUT4
10 skin papilloma 10.2 KRT20 MLH1 ODC1
11 gallbladder signet ring cell adenocarcinoma 10.2 CDH1 CTNNB1 KRT20
12 papillary transitional carcinoma 10.2 CASP3 CDH1 KRT20
13 uterine corpus endometrial stromal sarcoma 10.2 CEACAM5 KRT20 MLH1
14 small intestine carcinoid neuroendocrine tumor 10.2 ABCB1 CEACAM5 KRT20 TYMS
15 intestinal benign neoplasm 10.2 CEACAM5 FUT4 KRT20
16 prostate stromal sarcoma 10.2 CEACAM5 CTNNB1 KRT20
17 acute eustachian salpingitis 10.2 CDH1 CEACAM5 MLH1
18 wolffian duct adenoma 10.2 CEACAM5 KRT20 MLH1
19 trophoblastic neoplasm 10.2 CALB2 CEACAM5 KRT20
20 sphenoid sinus squamous cell carcinoma 10.2 CALB2 CEACAM5 KRT20
21 fallopian tube adenocarcinoma 10.2 CASP3 CEACAM5 KRT20 PTGS2
22 traumatic brain injury 10.2 CASP3 CDH1 CTNNB1
23 htr2a-related altered drug metabolism 10.2 MLH1 PTGS2
24 cranial nerve disease 10.2 CALB2 CEACAM5 KRT20
25 congenital symblepharon 10.2 CTNNB1 MLH1 ODC1 PTGS2
26 macrocytic anemia 10.2 CEACAM5 CTNNB1 ODC1 PTGS2
27 persian gulf syndrome 10.2 CALB2 CEACAM5 FUT4
28 pituitary carcinoma 10.2 CDH1 KRT20 PTGS2
29 lattice corneal dystrophy 10.2 CASP3 MLH1 PTGS2
30 in situ pulmonary adenocarcinoma 10.2 CASP3 CDH1 CTNNB1 PTGS2
31 cellular ependymoma 10.2 CALB2 CEACAM5 KRT20
32 odontotrichoungual-digital-palmar syndrome 10.2 CDH1 CEACAM5 KRT20 PTGS2
33 lung clear cell carcinoma 10.2 CALB2 CEACAM5 KRT20
34 rectum sarcoma 10.2 CEACAM5 KRT20 MLH1 TYMS
35 sarcomatoid basal cell carcinoma 10.2 CDH1 CEACAM5 FUT4 KRT20
36 asperger syndrome 10.2 CDH1 CTNNB1 MLH1 PTGS2
37 ladd syndrome 10.1 CASP3 CDH1 KRT20 PTGS2
38 ornithinemia 10.1 CASP3 CDH1 PTGS2
39 vestibular gland benign neoplasm 10.1 CEACAM5 CTNNB1 MLH1 PTGS2
40 paroxysmal nocturnal hemoglobinuria 10.1 CDH1 CEACAM5 CTNNB1
41 placenta praevia 10.1 CASP3 CDH1 CTNNB1 KRT20 PTGS2
42 immunodeficiency 37 10.1 CALB2 CDH1 CEACAM5 KRT20
43 malignant ovarian mixed epithelial neoplasm 10.1 ABCB1 CASP3 CTNNB1
44 rhinosporidiosis 10.1 ABCB1 CASP3 CDH1 CTNNB1 MLH1
45 ocular melanoma 10.1 CDH1 CEACAM5 CTNNB1 PTGS2
46 facial dermatosis 10.1 CDH1 CEACAM5 CTNNB1 MLH1 PTGS2
47 testicular cancer 10.0 CDH1 CEACAM5 KRT20 PTGS2
48 trachea squamous cell carcinoma 10.0 CASP3 CDH1 CEACAM5 CTNNB1 MLH1
49 bardet-biedl syndrome 10.0 CASP3 CDH1 CEACAM5 CTNNB1 MLH1
50 myotonic disease 10.0 CALB2 CDH1 CEACAM5 FUT4 KRT20

Graphical network of the top 20 diseases related to Colon Adenocarcinoma:



Diseases related to Colon Adenocarcinoma

Symptoms & Phenotypes for Colon Adenocarcinoma

MGI Mouse Phenotypes related to Colon Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 CDH1 CTNNB1 CTNND1 FUT4 MLH1 NQO1
2 digestive/alimentary MP:0005381 9.76 CTNNB1 CTNND1 MLH1 ABCB1 PTGS2 ST6GAL1
3 endocrine/exocrine gland MP:0005379 9.61 CDH1 CTNNB1 CTNND1 MLH1 ABCB1 ACSL4
4 neoplasm MP:0002006 9.17 CTNNB1 CTNND1 MLH1 NQO1 PTGS2 BAX

Drugs & Therapeutics for Colon Adenocarcinoma

Drugs for Colon Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 354)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
2
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
3
Iron Approved Phase 4,Phase 3 7439-89-6 23925
4
Benzocaine Approved Phase 4,Phase 2 1994-09-7, 94-09-7 2337
5
Zinc Approved Phase 4 7440-66-6 32051 23994
6 tannic acid Approved, Nutraceutical Phase 4,Phase 2
7 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
8 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Hypoglycemic Agents Phase 4,Phase 2
10 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 insulin Phase 4,Phase 2
12 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
13 Hepcidins Phase 4
14 Ferric Compounds Phase 4
15 Insulin, Globin Zinc Phase 4,Phase 2
16 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Omega 3 Fatty Acid Nutraceutical Phase 4
18 Iron Supplement Nutraceutical Phase 4
19
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
20
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
21
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
22
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
23
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
24
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
26
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
27
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
28
Raltitrexed Approved, Investigational Phase 3,Phase 2 112887-68-0 104758
29
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
30
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
31
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
32
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
33
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
34
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
35
Octreotide Approved, Investigational Phase 2, Phase 3 83150-76-9 383414 6400441
36
Ondansetron Approved Phase 3 99614-02-5 4595
37 Tegafur Approved Phase 3,Phase 2 17902-23-7
38
lanreotide Approved Phase 2, Phase 3 108736-35-2
39
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
40
Floxuridine Approved Phase 3,Phase 2,Phase 1 50-91-9 5790
41
Magnesium Sulfate Approved, Vet_approved Phase 3 7487-88-9 24083
42
Somatostatin Approved Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
43
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757 53477783
44
Glycerol Approved, Experimental Phase 3 56-81-5 753
45
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
46
Tinzaparin Approved Phase 3 9005-49-6, 9041-08-1 25244225
47
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
48
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
49
Dalteparin Approved Phase 3 9041-08-1
50
Nicotine Approved Phase 3 54-11-5 942 89594

Interventional clinical trials:

(show top 50) (show all 630)
id Name Status NCT ID Phase
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
2 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4
3 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4
4 A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma Completed NCT00097578 Phase 4
5 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4
6 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4
7 Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial Recruiting NCT02746432 Phase 4
8 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3
9 Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer Unknown status NCT00005979 Phase 3
10 Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Unknown status NCT00091312 Phase 3
11 Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00182715 Phase 3
12 Combination Chemotherapy in Treating Patients With Colon Cancer Unknown status NCT00046995 Phase 3
13 Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00070213 Phase 3
14 Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil Unknown status NCT00389870 Phase 3
15 Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00021281 Phase 3
16 Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00008281 Phase 3
17 Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00006468 Phase 3
18 Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer Unknown status NCT00003260 Phase 3
19 Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Unknown status NCT00274872 Phase 2, Phase 3
20 Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer Unknown status NCT00482222 Phase 3
21 Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver Unknown status NCT00002692 Phase 3
22 Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer Unknown status NCT00002893 Phase 3
23 J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma Unknown status NCT00070005 Phase 3
24 Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer Unknown status NCT00227747 Phase 3
25 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3
26 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
27 Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery Completed NCT00427310 Phase 3
28 Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver Completed NCT00023868 Phase 3
29 Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00003594 Phase 3
30 Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer Completed NCT00056446 Phase 3
31 Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. Completed NCT00056459 Phase 3
32 Combination Chemotherapy in Treating Patients With Stage III Colon Cancer Completed NCT00003835 Phase 3
33 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed NCT00079274 Phase 3
34 Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon Completed NCT00085163 Phase 3
35 Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery Completed NCT00660894 Phase 3
36 Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery Completed NCT00265811 Phase 3
37 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3
38 Combination Chemotherapy in Treating Patients With Resected Colon Cancer Completed NCT00378716 Phase 3
39 Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery Completed NCT00647530 Phase 3
40 Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer Completed NCT00002575 Phase 3
41 Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery Completed NCT00392899 Phase 3
42 Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer Completed NCT00026273 Phase 3
43 Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer Completed NCT00064181 Phase 3
44 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3
45 Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer Completed NCT00003873 Phase 3
46 Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases Completed NCT00268398 Phase 3
47 Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer Completed NCT00096278 Phase 3
48 Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM) Completed NCT00265824 Phase 3
49 Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Completed NCT00004252 Phase 3
50 Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated Completed NCT00025337 Phase 3

Search NIH Clinical Center for Colon Adenocarcinoma

Genetic Tests for Colon Adenocarcinoma

Anatomical Context for Colon Adenocarcinoma

MalaCards organs/tissues related to Colon Adenocarcinoma:

39
Colon, Liver, Lung, Lymph Node, T Cells, Bone, Myeloid

Publications for Colon Adenocarcinoma

Articles related to Colon Adenocarcinoma:

(show top 50) (show all 771)
id Title Authors Year
1
A microRNA expression signature as a predictor of survival for colon adenocarcinoma. ( 27881005 )
2017
2
18F-FDG PET/CT of Seminal Vesicle Metastasis From Ascending Colon Adenocarcinoma. ( 28005644 )
2017
3
TNF Signaling Through RIP1 Kinase Enhances SN38-induced Death in Colon Adenocarcinoma. ( 28087739 )
2017
4
Curcumin inhibits growth potential by G1 cell cycle arrest and induces apoptosis in p53-mutated COLO 320DM human colon adenocarcinoma cells. ( 28011386 )
2017
5
Hierridin B Isolated from a Marine Cyanobacterium Alters VDAC1, Mitochondrial Activity, and Cell Cycle Genes on HT-29 Colon Adenocarcinoma Cells. ( 27589771 )
2016
6
Maslinic Acid, a Natural Triterpene, Induces a Death Receptor-Mediated Apoptotic Mechanism in Caco-2 p53-Deficient Colon Adenocarcinoma Cells. ( 26751572 )
2016
7
Photodynamic action of palmatine hydrochloride on colon adenocarcinoma HT-29 cells. ( 27181460 )
2016
8
Single cutaneous metastasis of colon adenocarcinoma - Case report. ( 27579752 )
2016
9
Integrins are not essential for entry of coxsackievirus A9 into SW480 human colon adenocarcinoma cells. ( 27756316 )
2016
10
Same difference: A pilot study of cyclin D1, bcl-2, AMACR, and ALDH-1 identifies significant differences in expression between primary colon adenocarcinoma and its metastases. ( 27623206 )
2016
11
Olfactomedin 4 deletion induces colon adenocarcinoma in Apc(Min/+) mice. ( 26973250 )
2016
12
Maximizing the Therapeutic Efficacy of Imatinib Mesylate-Loaded Niosomes on Human Colon Adenocarcinoma Using Box-Behnken Design. ( 27544432 )
2016
13
Colonic Adenocarcinoma Presenting as Sigmoidorectal Intussusception: A Consideration for Intussusception Reduction. ( 27657559 )
2016
14
Co-expression of autophagic markers following photodynamic therapy in SW620 human colon adenocarcinoma cells. ( 27485939 )
2016
15
Potent In vivo anti-cancer activity and stability of liposomes encapsulated with semi-purified Job's tear (Coix lacryma-jobi Linn.) extracts on human colon adenocarcinoma (HT-29) xenografted mice. ( 27169326 )
2016
16
Glutaraldehyde-Mediated Synthesis of Asparaginase-Bound Maghemite Nanocomposites: Cytotoxicity against Human Colon Adenocarcinoma Cells. ( 27797224 )
2016
17
Synchronous Quadruple Primary Neoplasms: Colon Adenocarcinoma, Collision Tumor of Neuroendocrine Tumor and Schwann Cell Hamartoma and Sessile Serrated Adenoma of the Appendix. ( 27466549 )
2016
18
Analysis of the predictive efficiency of S100P on adverse prognosis and the pathogenesis of S100P-mediated invasion and metastasis of colon adenocarcinoma. ( 26975699 )
2016
19
Sorbus rufopilosa Extract Exhibits Antioxidant and Anticancer Activities by Inducing Cell Cycle Arrest and Apoptosis in Human Colon Adenocarcinoma HT29 Cells. ( 28053959 )
2016
20
Radiosensitizing potential of rutin against human colon adenocarcinoma HT-29 cells. ( 26925749 )
2016
21
Evaluation of lignan (-)-cubebin extracted from Piper cubeba on human colon adenocarcinoma cells (HT29). ( 26817788 )
2016
22
Identification of Molecular Targets for Predicting Colon Adenocarcinoma. ( 26868022 )
2016
23
Primula auriculata Extracts Exert Cytotoxic and Apoptotic Effects against HT-29 Human Colon Adenocarcinoma Cells. ( 27610172 )
2016
24
Drug membrane transporters and CYP3A4 are affected by hypericin, hyperforin or aristoforin in colon adenocarcinoma cells. ( 27261575 )
2016
25
Presentation of multiple myeloma mimicking bone metastasis from colon adenocarcinoma: A case report and literature review. ( 26870352 )
2016
26
Pneumobilia Resulting From Choledochoduodenal Fistula Secondary to Metastatic Colon Adenocarcinoma. ( 26958563 )
2016
27
Effect of different concentrations of oxygen on expression of sigma 1 receptor and superoxide dismutases in human colon adenocarcinoma cell lines. ( 27829319 )
2016
28
Modulation of transforming growth factora89I^ signaling transducers in colon adenocarcinoma cells induced by staphylococcal enterotoxin B. ( 26647993 )
2016
29
Endoplasmic reticulum stress, unfolded protein response and development of colon adenocarcinoma. ( 27220766 )
2016
30
In vitro anti-cancer activities of Job's tears (Coix lachryma-jobi Linn.) extracts on human colon adenocarcinoma. ( 26981007 )
2016
31
Sarcoid reaction: a rare occurrence associated to colon adenocarcinoma (case report and literature review). ( 27512605 )
2016
32
Iron overload of human colon adenocarcinoma cells studied by synchrotron-based X-ray techniques. ( 26759251 )
2016
33
Difficult Diagnosis of Colon Adenocarcinoma Metastasis to Retina: A Case Report and Literature Review. ( 27489594 )
2016
34
Modelling of survival of patients with colon adenocarcinoma based on multivariable analysis of the state of cancer cell nuclear apparatus. ( 27031719 )
2016
35
A Minimally Invasive Surgical Approach to Synchronous Anal and Colon Adenocarcinoma: Review of Existing Literature. ( 27021612 )
2016
36
Boletus edulis ribonucleic acid - a potent apoptosis inducer in human colon adenocarcinoma cells. ( 27302173 )
2016
37
Impact of Increased Visceral Fat Measured by CT on Colon Adenocarcinoma Stage. ( 27826814 )
2016
38
Combination of Nimbolide and TNF-I+-Increases Human Colon Adenocarcinoma Cell Death through JNK-mediated DR5 Up- regulation. ( 27268643 )
2016
39
Synchronous occurrence of appendiceal mucinous cystadenoma, with colon adenocarcinoma and tubulovillous rectal adenoma: Management and review of the literature. ( 27433069 )
2016
40
Serum availability affects expression of common house-keeping genes in colon adenocarcinoma cell lines: implications for quantitative real-time PCR studies. ( 27339468 )
2016
41
BRAFV600E Gene Mutation in Colonic Adenocarcinomas. Immunohistochemical Detection Using Tissue Microarray and Clinicopathologic Characteristics: An 86 Case Series. ( 25710585 )
2016
42
Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis: A case report. ( 27900088 )
2016
43
I^-Catenin Expression Regulates Cell Migration of Human Colonic Adenocarcinoma Cells Through Gelsolin. ( 27798885 )
2016
44
SYNCHRONOUS ANAL MELANOMA AND COLON ADENOCARCINOMA: CASE REPORT AND REVIEW OF DIAGNOSIS AND MANAGEMENT. ( 28076491 )
2016
45
Trends in lymph node excision and impact of positive lymph node ratio in patients with colectomy for primary colon adenocarcinoma: Population based study 1988 to 2011. ( 27566017 )
2016
46
Antiproliferative effects on colon adenocarcinoma cells induced by co-administration of vitamin K1 and Lactobacillus rhamnosus GG. ( 27035094 )
2016
47
SN-38 active loading in poly(lactic-co-glycolic acid) nanoparticles and assessment of their anticancer properties on COLO-205 human colon adenocarcinoma cells. ( 26381056 )
2015
48
Disseminated intravascular coagulation and immune hemolytic anemia, possibly evans syndrome, after oxaliplatin and bevacizumab infusion for metastatic colon adenocarcinoma: a case report and literature review. ( 25600448 )
2015
49
Lynch Syndrome Associated Colon Adenocarcinoma Resembling Lymphoma on Fluoro-Deoxyglucose-Positron Emission Tomography/Computed Tomography. ( 26420998 )
2015
50
Primary lung adenocarcinoma with enteric morphology associated with primary colon adenocarcinoma. ( 26163114 )
2015

Variations for Colon Adenocarcinoma

ClinVar genetic disease variations for Colon Adenocarcinoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 RAD54L NM_001142548.1(RAD54L): c.188C> A (p.Pro63His) single nucleotide variant Pathogenic rs121908688 GRCh37 Chromosome 1, 46715769: 46715769

Expression for Colon Adenocarcinoma

Search GEO for disease gene expression data for Colon Adenocarcinoma.

Pathways for Colon Adenocarcinoma

Pathways related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 19)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 BAX CASP3 CDH1 CTNNB1 PTGS2
2 12.23 BAX CASP3 CDH1 CTNNB1 MLH1 PTGS2
3
Show member pathways
12.07 BAX CASP3 CDH1 CTNNB1 MLH1
4
Show member pathways
11.72 CDH1 CTNNB1 CTNND1
5 11.71 CDH1 CEACAM5 CTNNB1 CTNND1
6 11.58 BAX CASP3 MLH1
7 11.56 CDH1 CTNNB1 CTNND1
8 11.54 BAX CASP3 CDH1 CTNNB1 ODC1
9 11.45 CASP3 CTNNB1 PTGS2
10 11.32 BAX CASP3 CDH1 CTNNB1 MLH1 PTGS2
11 11.31 CDH1 CTNNB1 CTNND1
12 11.26 CDH1 CTNNB1 CTNND1
13
Show member pathways
11.23 ABCB1 MLH1 NQO1
14 11.21 CDH1 CTNNB1 CTNND1
15 11.1 CDH1 CTNNB1 CTNND1
16 10.79 ABCB1 BAX CASP3
17 10.76 ABCB1 PTGS2
18 10.68 CDH1 CTNNB1
19 10.55 ABCB1 BAX

GO Terms for Colon Adenocarcinoma

Cellular components related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apical junction complex GO:0043296 9.26 CDH1 CTNNB1
2 catenin complex GO:0016342 9.16 CDH1 CTNNB1
3 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
4 cell periphery GO:0071944 8.8 BAX CTNNB1 FUT4

Biological processes related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.71 CASP3 NQO1 PTGS2 TYMS
2 kidney development GO:0001822 9.69 BAX CTNNB1 ODC1
3 response to organic substance GO:0010033 9.67 CASP3 CDH1 PTGS2
4 response to glucocorticoid GO:0051384 9.65 CASP3 PTGS2 TYMS
5 response to drug GO:0042493 9.63 ABCB1 CASP3 CDH1 CTNNB1 PTGS2 TYMS
6 response to toxic substance GO:0009636 9.62 BAX CDH1 NQO1 TYMS
7 response to estradiol GO:0032355 9.56 CASP3 CTNNB1 NQO1 PTGS2
8 adherens junction organization GO:0034332 9.54 CDH1 CTNNB1 CTNND1
9 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.46 BAX CASP3
10 cellular response to indole-3-methanol GO:0071681 9.43 CDH1 CTNNB1
11 entry of bacterium into host cell GO:0035635 9.13 CDH1 CTNNB1 CTNND1
12 positive regulation of neuron apoptotic process GO:0043525 8.92 BAX CASP3 CTNNB1 NQO1

Sources for Colon Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....